Choroidal Neovascularization Clinical Trial
— ATMOfficial title:
Identification of the Predisposing Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated)
Verified date | October 2018 |
Source | Fondation Ophtalmologique Adolphe de Rothschild |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Polypoidal choriodal vasculopathy (PCV) is an ophthalmologic disease, characterized by
vascular abnormalities of the walls of small choroidal vessels, reproducing the specific
aspect of polyps (cluster aspect). PCV is one of the "boundary-forms" of age related macular
degeneration.
These vasculopathies can be idiopathic. Following the radiotherapy treatments of active and
occult-typed neovessels in Age-Related Macular Degeneration (ARMD), 10% of the patients would
present typical polypoidal vasculopathic lesions. These polypoidal secondary lesions have
been induced by radiotherapy treatment and may show an increased sensibility to radiation in
these patients.
Such an increase of radiosensibility is noticed in ataxia telangiectasia syndrome, in
relation to the ATM gene mutations. The secondary or idiopathic polypoidal vasculopathic
lesions are to be brought closer to telangiectasias in Ataxia Telangiectasia. Considering the
iatrogenic component of radiotherapy in the secondary forms of ataxia telangiectasia, it
seems legitimate to search for predisposing variants to polypoidal vasculopathies in the ATM
gene.
Considering the frequency of PCV worldwide, it seems important to identify the predisposing
genetic factors of the ATM gene. These biomarkers to the pathology might enable us to offer
prevention (reinforced protection against radiations, including light) and to develop
therapeutics (recruitment of other kinases, ATM's partners, in the stability and cellular
control of DNA).
Status | Terminated |
Enrollment | 7 |
Est. completion date | October 23, 2018 |
Est. primary completion date | October 23, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Adult caucasian patient - Polypoidal choriodal vasculopathy - Informed written consent Exclusion Criteria: - History of cephalic radiotherapy - Absence of affiliation to social security or universal health coverage (CMU) |
Country | Name | City | State |
---|---|---|---|
France | Fondation Ophtalmologique A. de Rotchschild | Paris |
Lead Sponsor | Collaborator |
---|---|
Fondation Ophtalmologique Adolphe de Rothschild |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Variants in the ATM gene | Compared analysis of the variants frequency (heterozygote, homozygote variants versus the wild variant) in the ATM gene. | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01908816 -
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
|
Phase 3 | |
Completed |
NCT02015351 -
Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study
|
N/A | |
Withdrawn |
NCT01666236 -
Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy
|
Phase 4 | |
Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00533520 -
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
|
Phase 4 | |
Completed |
NCT00242580 -
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
|
Phase 3 | |
Completed |
NCT04075188 -
Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid
|
N/A | |
Not yet recruiting |
NCT05055973 -
OCTA Insights in CNVM, Morphological Characteristics and Correlation With Structural OCT.
|
||
Recruiting |
NCT00568191 -
Stratus Versus Cirrus OCT in AMD
|
N/A | |
Completed |
NCT01256632 -
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
|
N/A | |
Recruiting |
NCT00100087 -
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
|
Phase 1/Phase 2 | |
Completed |
NCT04455399 -
Time Efficiency Comparison of Two IntraVitreal Injection Techniques
|
N/A | |
Not yet recruiting |
NCT02934841 -
Conbercept in Choroidal Neovascularization Secondary to Uveitis
|
Phase 2 | |
Completed |
NCT01880788 -
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
|
N/A | |
Completed |
NCT00775411 -
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
|
Phase 2 | |
Completed |
NCT00604071 -
Sensitivity of the Home Macular Perimeter (HMP)
|
N/A | |
Withdrawn |
NCT00403156 -
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
|
Phase 1 | |
Completed |
NCT00406250 -
Intravitreal Bevacizumab in Agioid Streaks
|
Phase 1 | |
Completed |
NCT00251459 -
A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
|
Phase 3 |